Vildagliptin: all 152 studies that test it
Page 1 of 2. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- Efficacy of Vildagliptin Versus Metformin in Patients With Polycystic Ovary SyndromeNot yet recruitingNCT07811011Phase 2/3
- Clinical Trial of Vildagliptin in Early Parkinson's DiseaseNot yet recruitingNCT06951334Not applicable
- The Bioequivalence Study of Fixed-dose Combination of Vildagliptin and Metformin HCI 50/1000 mg FCT Under Fed ConditionsNot yet recruitingNCT06244407Phase 1
- Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary SyndromeRecruitingNCT06142656Phase 2/3
- Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DMRecruitingNCT03925701Phase 3
- Vildagliptin Versus Dapagliflozin on GlucagonCompletedNCT02475070Phase 4Results posted
- Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and GlimepirideCompletedNCT02007278Phase 4Results posted
- Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM PatientsCompletedNCT02002221Phase 4Results posted
- Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic PatientsTerminatedNCT01910441Phase 4Results posted
- Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 DiabetesCompletedNCT01882907Phase 4Results posted
- Vildagliptin/Metformin in T2DM Patients Starting Basal InsulinCompletedNCT01871558Phase 3Results posted
- Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 DiabetesCompletedNCT01822548Phase 3Results posted
- Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by MetforminCompletedNCT01766778Phase 4Results posted
- Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart FunctionCompletedNCT01686932Phase 4Results posted
- A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)CompletedNCT01582308Phase 1Results posted
- Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus PatientsCompletedNCT01582243Phase 4Results posted
- Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)CompletedNCT01537120Phase 1Results posted
- DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 DiabetesCompletedNCT01472432Phase 4Results posted
- Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk FactorsCompletedNCT07077525Phase 4
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.CompletedNCT06851962Phase 4
- Empagliflozin Versus Vildagliptin in CAD Patients With T2DMCompletedNCT06313008Not applicable
- Bioequivalence Study to Compare Metformin / Vildagliptin (850 mg/50 mg) Versus Galvumet®CompletedNCT06103747Phase 1
- Vildagliptin Versus Glimepiride in Type 2 Diabetic PatientsCompletedNCT06068686Not applicable
- Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes MellitusCompletedNCT05359432Phase 4
- The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed.CompletedNCT05329844Not applicable
- Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 DiabetesCompletedNCT04916093Phase 4
- Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment FailureCompletedNCT04841096Phase 3
- Vildagliptin for Treatment of Antipsychotic-induced DyslipidemiaWithdrawnNCT04761861Phase 2
- DPP4 Inhibitor on Glycemic VariabilityCompletedNCT04654676Phase 4
- Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications ProgressionStatus unknownNCT04485845Phase 4
- The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder PatientsWithdrawnNCT04410341Phase 1/2
- Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During RamadanCompletedNCT04237493Phase 4
- Vildagliptin in Older Adults With Diabetes and Mild Cognitive ImpairmentCompletedNCT03819127Phase 4
- Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CADCompletedNCT03693560Phase 4
- Vildagliptin on Gastric AccommodationCompletedNCT03500900Not applicable
- Metformin Versus Vildagliptin for Diabetic Hypertensive PatientsCompletedNCT03253562Phase 4
- Effects of DPP4 Inhibitor Versus SGLT2 InhibitorCompletedNCT03178591Phase 4
- A Clinical Trial to Study the Effects of Two Drugs, Vildagliptin and Metformin in Patients With Type 2 Diabetes MellitusCompletedNCT02853630Phase 4
- Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant PeriodCompletedNCT02849899Phase 3
- Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)CompletedNCT02816970Phase 1
- Monotherapy With Rapamycin in Long-standing Type 1 DiabetesCompletedNCT02803892Phase 2
- Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) SecretionCompletedNCT02749032Phase 1
- Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and HypertensionCompletedNCT02145611Phase 4
- Glycemic Durability After Metformin FailureStatus unknownNCT02142309Phase 4
- DPP-4 Inhibition, Incretins and Islet FunctionCompletedNCT02089438Phase 4
- Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 DiabetesStatus unknownNCT01867502Phase 4
- Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II DiabetesTerminatedNCT01862263Phase 4
- Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese WomenCompletedNCT01827280Phase 4
- Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During RamadanCompletedNCT01758380Phase 4
- Galvus (Vildagliptin) vs Placebo in Combination With Metformin and InsulinCompletedNCT01757587Phase 4
- Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and SaxagliptinStatus unknownNCT01703637Not applicable
- Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic VariabilityCompletedNCT01679899Phase 4
- Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.CompletedNCT01649466Phase 4
- Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery DiseaseCompletedNCT01604213Phase 4
- Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes MellitusCompletedNCT01582230Phase 3
- Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin MonotherapyStatus unknownNCT01565096Phase 4
- Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes MellitusStatus unknownNCT01559025Phase 3
- Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)CompletedNCT01541956Phase 4
- Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both MedicationsCompletedNCT01518101Phase 4
- Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 DiabetesCompletedNCT01497522Phase 3
- Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) TherapyCompletedNCT01452113Phase 2
- Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With MetforminCompletedNCT01426802Phase 4
- The Swiss Glucose Variability StudyStatus unknownNCT01426737Phase 4
- Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering EfficacyCompletedNCT01398592Phase 4
- Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 DiabetesCompletedNCT01357252Phase 3
- Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 DiabetesCompletedNCT01356381Phase 4
- Glucose Control in Pre-Diabetic Renal Transplant PatientsCompletedNCT01346254Phase 2
- Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 DiabetesStatus unknownNCT01339143Phase 4
- Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 DiabetesCompletedNCT01309698Phase 4
- Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.CompletedNCT01262586Phase 3
- Safety and Efficacy of Galvus in Elderly Type 2 Diabetes PatientsCompletedNCT01257451Phase 3
- Phase 4 Study in the Elderly Patients With T2DMCompletedNCT01238978Phase 4
- Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus GlimepirideCompletedNCT01233622Phase 3
- Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes MellitusCompletedNCT01224366Phase 3
- Vildagliptin and the Glucagon Response to Hypoglycemia in Insulin-Treated Patients With Type 2 DiabetesCompletedNCT01219400Phase 4
- Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)CompletedNCT01196546Phase 4
- Glycemic Holter Study (Continuous Glucose Monitoring) -CompletedNCT01193296Phase 4
- Long-term Safety Study of Vildagliptin in Patients With Type 2 DiabetesCompletedNCT01159249Phase 3
- Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 DiabetesCompletedNCT01147276Phase 4
- The Vascular Effects of Vildagliptin in Insulin Resistant IndividualsCompletedNCT01122641Phase 3
- Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and MetforminCompletedNCT01099137Phase 4
- Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)Status unknownNCT01083992Not applicable
- PINGUIN (Postpartum Intervention in Women With Gestational Diabetes Using Insulin)Status unknownNCT01018602Phase 2
- Vildagliptin and Endothelium-dependent VasodilatationCompletedNCT01000688Phase 3
- Vildagliptin in New Onset Diabetes After TransplantationCompletedNCT00980356Phase 2
- Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes MellitusCompletedNCT00975065Phase 4
- The Effects of LAF237 on Gastric Function in Type 2 DiabetesCompletedNCT00952991Phase 3
- Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).WithdrawnNCT00936234Phase 2/3
- Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart FailureCompletedNCT00894868Phase 4
- Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 DiabetesCompletedNCT00860288Phase 2/3
- Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin MonotherapyCompletedNCT00822211Phase 3
- Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 DiabetesCompletedNCT00821977Phase 2/3
- Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired PatientsCompletedNCT00818571Phase 1/2
- Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)CompletedNCT00770081Phase 3
- Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)CompletedNCT00765830Phase 3
- Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)CompletedNCT00728351Phase 3
- Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy SubjectsCompletedNCT00651105Phase 3
- Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal InsufficiencyCompletedNCT00646542Phase 3
- Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 DiabetesTerminatedNCT00633997Phase 1/2
- Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal InsufficiencyCompletedNCT00616811Phase 3